Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib in Platinum-Pretreated NSCLC with EGFR Exon 20 Insertion
NCT05712902Phase 2Active, not recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jul 2021; status: active, not recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05712902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712902.